Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Einsele, Hermann  [Clear All Filters]
2024
Werner R, Haug A, Buske C, Heidegger S, Illert AL, Bassermann F, Herhaus P, Buck A, Duell J, Topp MS, et al. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin. 2024.
2023
Weller JFrederic, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, et al. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. Haematologica. 2023.
Bader P, Rossig C, Hutter M, Ayuk FAyuketang, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, et al. CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany. Blood Adv. 2023.
Lauruschkat CDavid, Muchsin I, Rein A, Erhard F, Grathwohl D, Dölken L, Köchel C, Falk CSusanne, Einsele H, Wurster S, et al. CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis. Front Immunol. 2023;14:1148841.
Dreher N, Dörrler A-L, Kraus S, Higuchi T, Serfling SE, Samnick S, Einsele H, Grigoleit GUlrich, Buck AK, Werner RA. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile. Clin Nucl Med. 2023.
Hartlapp I, Hartrampf PE, Serfling SE, Wild V, Weich A, Rasche L, Roth S, Rosenwald A, Mihatsch PW, Hendricks A, et al. CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors. J Nucl Med. 2023.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, P Ho J, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2023.
Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Valerius T, Klein S, Kröger N, Wulf G, Einsele H, Thurner L, et al. KIR2DS4 and its variant KIR1D in KIR-AA genotype donors showed differential survival impact in patients with lymphoid disease after HLA-matched unrelated hematopoietic stem cell transplantation. Transplant Cell Ther. 2023.
Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269.
Kegyes D, Gulei D, Drula R, Cenariu D, Tigu B, Dima D, Tanase A, Badelita S, Buzoianu A-D, Ciurea S, et al. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev. 2023:101100.
Buck AK, Serfling SE, Kraus S, Samnick S, Dreher N, Higuchi T, Rasche L, Einsele H, Werner RA. Theranostics in Hematooncology. J Nucl Med. 2023.
2022
Gagelmann N, Wulf GGeorg, Duell J, Glass B, van Heteren P, von Tresckow B, Fischer M, Penack O, Ayuk FA, Einsele H, et al. Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study. Blood Adv. 2022.
2021
Straka C, Salwender H, Knop S, Vogel M, Müller J, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, et al. Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. Eur J Haematol. 2021.
Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen CMathilde, Yeguas A, Vidriales M-B, González M, Saborido JRial, Kraus S, et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML). Blood. 2021.
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118.
2020
Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020.
2019
Luber V, Lutz M, Abele-Horn M, Einsele H, Grigoleit GUlrich, Mielke S. Excretion of Ascaris lumbricoides following reduced-intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole. Transpl Infect Dis. 2019:e13224.
Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019.
2018
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, et al. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2018.
2016
Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke C, Wandt H, Bentz M, et al. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016.
Albiero E, Amati E, Baumeister E, Einsele H, Grigoleit GU, Rodeghiero F. Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens. J Immunother. 2016.
2015
Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, Recher M, Gruhn B, Holbro A, Heijnen I, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. 2015.
Mueller-Leisse J, Brueggemann S, Bouzani M, Schmitt A-L, Einsele H, Loeffler J. Polymorphonuclear neutrophils and granulocytic myeloid-derived suppressor cells inhibit natural killer cell activity toward Aspergillus fumigatus. Med Mycol. 2015.
Fuji S, Einsele H, Savani BN, Kapp M. Systematic nutritional support in allogeneic HSCT recipients. Biol Blood Marrow Transplant. 2015.
2014
Einsele H, Mielke S, Grigoleit GUlrich. Diagnosis and treatment of cytomegalovirus 2013. Curr Opin Hematol. 2014;21(6):470-475.

Pages